CAR-T
From Partnership to Acquisition: The $1.5 Billion Journey of Roche and Poseida Therapeutics
Roche Holdings/ Inc., Poseida Therapeutics/ Inc., Allogeneic cell therapy, CAR-T programs, Genetic medicines, Biotech acquisition, Pharmaceutical industry
Roche Acquires Poseida Therapeutics for Up to $1.5 Billion, Expanding Off-the-Shelf CAR-T Capabilities
Roche, Poseida Therapeutics, CAR-T therapy, off-the-shelf cell therapies, allogeneic cell therapy, biotech acquisition
Roche Acquires CAR-T Partner Poseida Therapeutics for $1 Billion Upfront
Roche, Poseida Therapeutics, CAR-T, cell therapy, acquisition, biotechnology, pharmaceuticals
Allogene Halts Leukemia CAR-T Trial Enrollment Due to Breyanzi Competition
Allogene, CAR-T therapy, leukemia, Breyanzi, Bristol Myers Squibb, cema-cel, clinical trials
Gilead and Arcellx Present Promising CAR-T Therapy Data for Advanced Multiple Myeloma, Highlighting Safety and Efficacy Against Carvykti
Gilead, Arcellx, CAR-T therapy, multiple myeloma, anito-cel, Carvykti, ASH 2024, safety profile, efficacy, relapsed/refractory multiple myeloma
AvenCell Therapeutics Secures $112 Million Series B Funding for Revolutionary ‘Switchable’ CAR-T Cell Therapy
AvenCell Therapeutics, Series B Funding, CAR-T Cell Therapy, Switchable CAR-Ts, Clinical Trials, Biotech Innovation
J&J and Legend’s Carvykti Demonstrates Significant Survival Benefit in Earlier-Line Multiple Myeloma Treatment
Carvykti, multiple myeloma, CAR-T therapy, Johnson & Johnson, Legend Biotech, CARTITUDE-4, survival benefit, second-line treatment
Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun
Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta
Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma
Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta
ArsenalBio Secures $325M Funding to Advance Programmable CAR-T Therapies
ArsenalBio, CAR-T therapies, biotech funding, programmable cell therapies, solid tumors, Regeneron, BMS